497 related articles for article (PubMed ID: 32266098)
1. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
[TBL] [Abstract][Full Text] [Related]
2. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Yan L; Matsuyama R; Ishikawa T; Endo I; Takabe K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971948
[TBL] [Abstract][Full Text] [Related]
3. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients.
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
J Immunol Res; 2020; 2020():5618786. PubMed ID: 33457427
[TBL] [Abstract][Full Text] [Related]
4. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC).
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Kalinski P; Endo I; Takabe K
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198125
[TBL] [Abstract][Full Text] [Related]
5. Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC).
Tokumaru Y; Oshi M; Murthy V; Tian W; Yan L; Angarita FA; Nagahashi M; Matsuhashi N; Futamura M; Yoshida K; Miyoshi Y; Takabe K
Am J Cancer Res; 2021; 11(11):5743-5755. PubMed ID: 34873491
[TBL] [Abstract][Full Text] [Related]
6. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival.
Wu R; Oshi M; Asaoka M; Huyser MR; Tokumaru Y; Yamada A; Yan L; Endo I; Ishikawa T; Takabe K
Am J Cancer Res; 2022; 12(2):744-762. PubMed ID: 35261799
[TBL] [Abstract][Full Text] [Related]
8. High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer.
Tokumaru Y; Asaoka M; Oshi M; Katsuta E; Yan L; Narayanan S; Sugito N; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370060
[TBL] [Abstract][Full Text] [Related]
9. A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.
Yang A; Wu M; Ni M; Zhang L; Li M; Wei P; Yang Y; Xiao W; An X
Breast Cancer; 2022 May; 29(3):468-477. PubMed ID: 35061208
[TBL] [Abstract][Full Text] [Related]
10. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment.
Obr AE; Kumar S; Chang YJ; Bulatowicz JJ; Barnes BJ; Birge RB; Lazzarino DA; Gallagher E; LeRoith D; Wood TL
Breast Cancer Res; 2018 Nov; 20(1):138. PubMed ID: 30458886
[TBL] [Abstract][Full Text] [Related]
12. Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer.
Deng L; Lu D; Bai Y; Wang Y; Bu H; Zheng H
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):1977-1985. PubMed ID: 31533938
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment.
Gandhi S; Oshi M; Murthy V; Repasky EA; Takabe K
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071012
[TBL] [Abstract][Full Text] [Related]
14. Increased apoptosis is associated with robust immune cell infiltration and cytolytic activity in breast cancer.
Murthy V; Oshi M; Tokumaru Y; Endo I; Takabe K
Am J Cancer Res; 2021; 11(7):3674-3687. PubMed ID: 34354867
[TBL] [Abstract][Full Text] [Related]
15. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
O'Meara T; Marczyk M; Qing T; Yaghoobi V; Blenman K; Cole K; Pelekanou V; Rimm DL; Pusztai L
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923897
[TBL] [Abstract][Full Text] [Related]
16. Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis.
Okano M; Oshi M; Butash AL; Katsuta E; Tachibana K; Saito K; Okayama H; Peng X; Yan L; Kono K; Ohtake T; Takabe K
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461932
[TBL] [Abstract][Full Text] [Related]
17. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
19. Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer.
Oshi M; Roy AM; Yan L; Sasamoto M; Tokumaru Y; Wu R; Yamada A; Yamamoto S; Chishima T; Narui K; Endo I; Takabe K
Am J Cancer Res; 2023; 13(7):3041-3054. PubMed ID: 37559984
[TBL] [Abstract][Full Text] [Related]
20. High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.
Oshi M; Tokumaru Y; Benesch MG; Sugito N; Wu R; Yan L; Yamada A; Chishima T; Ishikawa T; Endo I; Takabe K
Am J Cancer Res; 2022; 12(10):4840-4852. PubMed ID: 36381329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]